CYP19A1 and hyperlipidemia: Women treated with aromatase inhibitors, indeed, compared with patients who receive tamoxifen, are more likely to develop hyperlipidemia, hypercholesterolemia, and hypertension, which are recognized cardiovascular (CV) risk factors [4].